BACKGROUND: The incidence of Ewing's tumors (ETs) is lower in Asians or African-Americans than in Caucasians. PATIENTS AND METHODS: Japanese ETs were available for analysis of chromosomal aberrations by comparative genomic hybridization (n = 16) and for expression of chimeric EWS transcripts by reverse-transcriptase polymerase chain reaction (n = 11). These results in Japanese patients were compared with those of 62 ETs in European Caucasian patients registered in the European Intergroup Cooperative Ewing's Sarcoma Study. RESULTS: Japanese patients with ET had lower overall survival (P = 0.0446) and relapse-free survival (P = 0.0371) compared with European Caucasian patients. Ten of 11 Japanese ETs and 31 of 62 European Caucasian ETs had type I (EWS exon 7 to FLI1 exon 6) fusion transcripts. In Japanese ETs, the median numbers of chromosomal aberrations were 2.0 and 6.0 in 11 primary tumors and five relapsed tumors, respectively. In European Caucasian ETs, the median number of changes were 2.5 and 5.0 in 52 primary and 10 relapsed tumors, respectively. Frequent gains were 8q (38%), 8p (31%) and 12q (25%) in Japanese ETs and 8q (52%), 8p (48%) and 12q (19%) in European Caucasian ETs. Frequent losses were 19q (44%), 19p (38%) and 17p (25%) in Japanese ETs and 16q (21%), 19q (18%) and 17p (15%) in European Caucasian ETs. The incidence of losses of 19p (P = 0.0215) and 19q (P = 0.0277) were significantly higher in Japanese ETs than in European Caucasian ETs. An amplification (1p33-p34) was observed in only one Japanese ET. CONCLUSIONS: Japanese patients with ET in this study had a worse prognosis than European Caucasian patients. In molecular genetic analyses, Japanese ETs had a higher frequency of loss of chromosome 19 than European Caucasian ETs. Different genetic aberrations may explain the different incidences and prognoses of ET between Caucasian and Japanese patients.
BACKGROUND: The incidence of Ewing's tumors (ETs) is lower in Asians or African-Americans than in Caucasians. PATIENTS AND METHODS: Japanese ETs were available for analysis of chromosomal aberrations by comparative genomic hybridization (n = 16) and for expression of chimeric EWS transcripts by reverse-transcriptase polymerase chain reaction (n = 11). These results in Japanese patients were compared with those of 62 ETs in European Caucasian patients registered in the European Intergroup Cooperative Ewing's Sarcoma Study. RESULTS: Japanese patients with ET had lower overall survival (P = 0.0446) and relapse-free survival (P = 0.0371) compared with European Caucasian patients. Ten of 11 Japanese ETs and 31 of 62 European Caucasian ETs had type I (EWS exon 7 to FLI1 exon 6) fusion transcripts. In Japanese ETs, the median numbers of chromosomal aberrations were 2.0 and 6.0 in 11 primary tumors and five relapsed tumors, respectively. In European Caucasian ETs, the median number of changes were 2.5 and 5.0 in 52 primary and 10 relapsed tumors, respectively. Frequent gains were 8q (38%), 8p (31%) and 12q (25%) in Japanese ETs and 8q (52%), 8p (48%) and 12q (19%) in European Caucasian ETs. Frequent losses were 19q (44%), 19p (38%) and 17p (25%) in Japanese ETs and 16q (21%), 19q (18%) and 17p (15%) in European Caucasian ETs. The incidence of losses of 19p (P = 0.0215) and 19q (P = 0.0277) were significantly higher in Japanese ETs than in European Caucasian ETs. An amplification (1p33-p34) was observed in only one Japanese ET. CONCLUSIONS: Japanese patients with ET in this study had a worse prognosis than European Caucasian patients. In molecular genetic analyses, Japanese ETs had a higher frequency of loss of chromosome 19 than European Caucasian ETs. Different genetic aberrations may explain the different incidences and prognoses of ET between Caucasian and Japanese patients.
Authors: Karl-Ludwig Schaefer; Kristin Brachwitz; Yvonne Braun; Raihanatou Diallo; Daniel H Wai; Susanne Zahn; Dominik T Schneider; Cornelius Kuhnen; Arabel Vollmann; Gero Brockhoff; Helmut E Gabbert; Christopher Poremba Journal: Neoplasia Date: 2006-07 Impact factor: 5.715
Authors: R L Randall; S L Lessnick; K B Jones; L G Gouw; J E Cummings; L Cannon-Albright; J D Schiffman Journal: J Oncol Date: 2010-03-15 Impact factor: 4.375
Authors: Jeremy Sharib; Andrew Horvai; Florette K Gray Hazard; Heike Daldrup-Link; Robert Goldsby; Neyssa Marina; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2013-08-23 Impact factor: 3.167
Authors: Richard J Q McNally; Karen Blakey; Roger C Parslow; Peter W James; Basilio Gómez Pozo; Charles Stiller; Tim J Vincent; Paul Norman; Patricia A McKinney; Michael F Murphy; Alan W Craft; Richard G Feltbower Journal: BMC Cancer Date: 2012-06-27 Impact factor: 4.430
Authors: Logan G Spector; Aubrey K Hubbard; Brandon J Diessner; Mitchell J Machiela; Beau R Webber; Joshua D Schiffman Journal: Int J Cancer Date: 2021-05-17 Impact factor: 7.316
Authors: Songfeng Chen; Lin Yang; Feifei Pu; Hui Lin; Baichuan Wang; Jianxiang Liu; Zengwu Shao Journal: Int J Environ Res Public Health Date: 2015-09-09 Impact factor: 3.390
Authors: Juhee Seo; Dong Ho Kim; Jung Sub Lim; Jae-Soo Koh; Ji Young Yoo; Chang-Bae Kong; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Jun Ah Lee Journal: Korean J Pediatr Date: 2013-09-30